Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

JERUSALEM, May 18, 2026 – Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported first quarter 2026 financial results and provided a corporate update. – Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% […]

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026. Event: H.C. Wainwright 4th Annual BioConnect Investor Conference Format: Fireside Chat and […]